Pink SheetKisunla (donanemab) is on track to be authorized for marketing in the EU, after the European Medicines Agency reversed its previous recommendation against approving the amyloid-targeting, disease modi
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis, Matchpoint Will Seek Out Oral
Pink SheetThe European Medicines Agency has recommended that Gilead Sciences’ Yeytuo (lenacapavir), for preventing HIV, and 13 other new drugs should be granted pan-EU marketing authorization, but it has advise
ScripGilead Sciences’ Yeytuo (lenacapavir) and Eli Lilly’s Kisunla (donanemab) are among the drugs that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for